By Josh Beckerman
Processa Pharmaceuticals shares surged after the company reported a binding term sheet granting Intact Therapeutics an exclusive option to license a gastroparesis drug candidate but then retreated after Processa announced a $7 million equity offering.
Shares were recently at 30 cents, up 34%, compared with an intraday high of 79 cents.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 17, 2025 12:48 ET (16:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.